Tag Archives: Eldepryl

Alzheimer’s Therapy: Natural Antioxidants

Overview. Natural antioxidants exhibit a degree of neuroprotection by neutralizing reactive oxygen species (ROS) that accumulate in the brain as a result of age and perhaps as the result of amyloid plaque formation. Unlike acetylcholinesterase inhibitors, which target the symptoms of Alzheimer’s disease as the disease progresses, antioxidants may act in a preventive fashion by… Read More »

Minor Depression

Etiology and Pathophysiology Minor depression is only a proposed diagnosis in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, and there are no International Classification of Diseases codes to categorize it. The proposed diagnostic category for minor depression in Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition describes a depressive disorder that… Read More »

Long-term care for the patient with dementia

Services for most people with dementia begin and, for many, end in the community. Institutional care is an important part of the total package of dementia care and some forms of institutional care prolong the period of time people with dementia can continue to live at home. By supporting carers and providing temporary respite and… Read More »

Design and long-term care

Any design of a long term care facility is inevitably a compromise. On the one hand are the requirements of the patient — for the facility to be as like the normal home environment as possible, and on the other hand are the requirements that the facility be manageable — that residents can be seen… Read More »

Disease Modification

The revolution in treatment of Alzheimer’s disease of the acetylcholin esterase inhibitor (ACHEI) is all very well, but they were designed as symptomatic treatments and, ultimately, therapies that are truly useful in Alzheimer’s disease will be disease-modifying. Where will such therapies come from? Serendipity is usually the answer but rationally designed disease-modification strategies are likely… Read More »

Targeting tau

The importance of tau to the pathology of dementia came with genetic discoveries (as it so often does). Highly phosphorylated tau, a microtubule-associated protein, essential for normal neuronal functioning, aggregates in neurofibrillary tangles in Alzheimer’s disease and in other dementias. The phosphorylation of tau reduces its normal function by reducing its binding to tangles ().… Read More »

Monoamine Oxidase Inhibitor

Monoamine oxidase (MAO) inhibitors are one of the two oldest classes of antidepressants, having been discovered to have antidepressant properties in the early 1950s. After the development of agents that were less toxic than the first monoamine oxidase inhibitor (iproniazid), they were second-line agents after the tricyclics. However, over the last 20 years, with the… Read More »

Narcolepsy Due To Medical Condition

Several cases of narcolepsy in association with brain tumors have been reported. Narcolepsy has also been reported in patients with multiple sclerosis, encephalitis, cerebral ischemia, cranial trauma, brain tumor, and cerebral degeneration. Hypothalamic sarcoidosis has caused narcolepsy in at least two cases, although neither had cataplexy. Symptomatic narcolepsies are also present in children affected with… Read More »


Narcolepsy is characterized as a disorder in which the boundaries of wakefulness and normal sleep, most notably rapid eye movement sleep, are blurred; features of sleep intrude into the state of wakefulness and vice versa. It has been divided into various categories, including those with cataplexy, those without cataplexy, those due to a medical condition… Read More »